Focusing on scRNA-seq-Derived T Cell-Associated Genes to Identify Prognostic Signature and Immune Microenvironment Status in Low-Grade Glioma

Figure 6

Evaluation of immunotherapy effect. (a–c) In the PRJEB23709 cohort, the bar chart shows the proportion of patients in the high- and low-risk groups who responded to immunotherapy. The box plot shows the risk score for different immunotherapy effects. The K-M survival analysis shows the clinical outcome of the high- and low-risk groups. (d–i) In the GSE78820 and IMvigor-210 cohorts. The bar chart shows the proportion of patients in the high- and low-risk groups who responded to immunotherapy. The box plot shows the risk score for different immunotherapy effects. The K-M survival analysis shows the clinical outcome of the high- and low-risk groups. (j) The bar chart shows the AUC values for each biomarker used to predict immunotherapy.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)